keyword
MENU ▼
Read by QxMD icon Read
search

Cancer Related Fatigue

keyword
https://www.readbyqxmd.com/read/29789774/pilot-study-of-dose-response-effects-of-exercise-on-change-in-c-reactive-protein-cortisol-and-health-related-quality-of-life-among-cancer-survivors
#1
Jeanette M Ricci, Victoria Flores, Isabela Kuroyama, Arash Asher, Heather P Tarleton
Fatigue, stress, and depression contribute to poor health-related quality of life (HRQoL) among cancer survivors. This study examined the effects of combined aerobic and resistance training (CART) on HRQoL and biomarkers of stress. Cancer survivors ( n  = 76, 91% female, 39% breast cancer, 32% gynecologic cancer) were enrolled in CART for three 60-min sessions, weekly, for 26 weeks. Participants completed the National Institutes of Health's Patient Reported Outcomes Measurement Information System (NIH PROMIS) fatigue assessment and the SF-36...
2018: BioResearch Open Access
https://www.readbyqxmd.com/read/29787376/symptom-assessment-to-guide-treatment-selection-and-determine-progression-in-metastatic-castration-resistant-prostate-cancer-expert-opinion-and-review-of-the-evidence
#2
REVIEW
Fred Saad, Frédéric Pouliot, Brita Danielson, Charles Catton, Anil Kapoor
Multiple new agents to treat metastatic castration-resistant prostate cancer (mCRPC) have become available in recent years; however, the appropriate timing and sequencing of these agents have yet to be elucidated. Until accurate biomarkers become available to allow more focused therapeutic targeting for this population, treatment selection for men with mCRPC will continue to be driven largely by close assessment of patient-related factors and symptoms. Pain, as the predominant symptom of mCRPC, is often the focus when assessing progression and the need for a change in treatment...
May 14, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29785939/exploring-an-integrative-patient-tailored-complementary-medicine-approach-for-chemotherapy-induced-taste-disorders
#3
Eran Ben-Arye, Ilana Doweck, Elad Schiff, Noah Samuels
CONTEXT: Chemotherapy-induced taste disorder (CITD) is a common adverse effect among patients with cancer, with no effective known treatment. OBJECTIVES: Exploring the impact of a patient-tailored complementary and integrative medicine (CIM) treatment program on CITD-related severity. DESIGN: Prospective study on patients' chart. SETTING: Integrative oncology program operating within the Clalit Healthcare Oncology Service in northern Israel...
April 22, 2018: Explore: the Journal of Science and Healing
https://www.readbyqxmd.com/read/29778506/quality-of-life-symptoms-and-care-needs-in-patients-with-persistent-or-recurrent-platinum-resistant-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#4
Vivian E von Gruenigen, Helen Q Huang, David Cella, MichaelA Zevon, Jason A LaChance, Joan L Walker, Ritu Salani, Susan C Modesitt, Robert T Morris, William H Bradley, Matthew P Boente, Lari Wenzel
OBJECTIVES: The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs. METHODS: Eligible women included those with persistent or recurrent platinum-resistant ovarian cancer with an estimated life expectancy of at least 6 months. The Needs at the End-of-Life Screening Tool (NEST), FACIT-Fatigue (FACIT-F), NCCN-FACT Ovarian Symptom Index [NFOSI-18]; Disease Related Symptoms (DRS), Treatment Side Effects (TSE), and Function/Well Being (F/WB) were collected at study entry, 3 and 6 months...
May 17, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29771164/retrospective-evaluation-of-clinical-experience-with-intravenous-ascorbic-acid-in-patients-with-cancer
#5
Anthony J Bazzan, George Zabrecky, Nancy Wintering, Andrew B Newberg, Daniel A Monti
BACKGROUND: Intravenous ascorbic acid (IV AA) has been used extensively in cancer patients throughout the United States. Currently, there are limited data on the safety and clinical effects of IV AA. The purpose of this study was to expand the current literature using a retrospective analysis of adverse events and symptomatic changes of IV AA in a large sample of cancer patients. METHODS: We conducted a retrospective chart review of all patients receiving IV AA for cancer at the Thomas Jefferson University Hospital over a 7-year period...
May 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29770225/quality-of-life-of-irradiated-brain-tumor-survivors-treated-with-donepezil-or-placebo-results-of-the-wfu-ccop-research-base-protocol-91105
#6
Michelle J Naughton, L Douglas Case, Ann Peiffer, Michael Chan, Volker Stieber, Dennis Moore, Steven Falchuk, James Piephoff, William Edenfield, Jeffrey Giguere, Monica Loghin, Edward G Shaw, Stephen R Rapp
Background: The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. Methods: One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks...
May 2018: Neuro-oncology Practice
https://www.readbyqxmd.com/read/29768958/bevacizumab-induced-atypical-hemolytic-uremic-syndrome-and-treatment-with-eculizumab
#7
Anusha Vakiti, Daulath Singh, Ravi Pilla, Muhamad A Moustafa, Kelly W Fitzpatrick
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29767832/cancer-survivors-exhibit-a-different-relationship-between-muscle-strength-and-health-related-quality-of-life-fatigue-compared-to-healthy-subjects
#8
S Morishita, A Tsubaki, J B Fu, Y Mitobe, H Onishi, T Tsuji
We investigated the difference in relationship between muscle strength and quality of life (QOL)/fatigue in long-term cancer survivors and healthy subjects. Thirty-six cancer survivors and 29 healthy subjects were assessed for body composition and bone status at the calcaneus using the Osteo Sono Assessment Index. Muscle strength was evaluated via handgrip and knee extensor strength. Health-related QOL was assessed using the Medical Outcome Study 36-item Short-Form Health Survey. Fatigue was measured using the brief fatigue inventory...
May 16, 2018: European Journal of Cancer Care
https://www.readbyqxmd.com/read/29766337/a-phase-i-trial-to-determine-safety-and-pharmacokinetics-of-aslan002-an-oral-met-superfamily-kinase-inhibitor-in-patients-with-advanced-or-metastatic-solid-cancers
#9
Aflah Roohullah, Adam Cooper, Anna J Lomax, Jennifer Aung, Alan Barge, Lilian Chow, Mark McHale, Jayesh Desai, James R Whittle, Ben Tran, Paul de Souza, Lisa G Horvath
Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion. ASLAN-002 is a potent inhibitor of MET as well as related kinases. A phase I dose escalation study was conducted to determine the safety and pharmacokinetics of ASLAN-002 in patients with advanced cancer. Methods Patients with advanced or metastatic solid tumours, who had progressed on standard therapy or for whom standard therapy was not known, were administered ASLAN-002 orally...
May 16, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29764800/mindfulness-based-symptom-and-stress-management-apps-for-adults-with-chronic-lung-disease-systematic-search-in-app-stores
#10
REVIEW
Otis L Owens, Jenay M Beer, Ligia I Reyes, David G Gallerani, Amanda R Myhren-Bennett, Karen K McDonnell
BACKGROUND: Up to 70% of lung cancer survivors are affected by chronic obstructive pulmonary disease (COPD), a common, debilitating, comorbid disease. Lung cancer and COPD are both characterized by symptoms such as breathlessness, fatigue, and psychological distress. These distressing chronic symptoms are exacerbated by stress and detract from an individual's quality of life. OBJECTIVE: The aim of this study was to identify and evaluate evidence-based, commercially available apps for promoting mindfulness-based strategies among adults with a COPD or lung cancer history (ie, chronic lung disease)...
May 15, 2018: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/29763737/validation-of-inflammatory-genetic-variants-associated-with-long-term-cancer-related-fatigue-in-a-large-breast-cancer-cohort
#11
T Kühl, S Behrens, A Jung, N Obi, K Thöne, M E Schmidt, H Becher, J Chang-Claude
BACKGROUND: Studies to date have reported several associations between single nucleotide polymorphisms (SNPs) and cancer related fatigue (CRF), but have been limited by small sample sizes, missing adjustment for relevant covariates or multiple testing, as well as varying CRF definitions, i.e. time and method of assessment. This study aimed to validate previously reported associations using the largest independent breast cancer sample to date and to evaluate further functional cytokine variants in relation to total CRF and all relevant CRF subdomains (physical, cognitive, and affective CRF)...
May 12, 2018: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/29756245/age-related-differences-in-health-related-quality-of-life-among-thyroid-cancer-survivors-compared-with-a-normative-sample-results-from-the-profiles-registry
#12
Floortje Mols, Dounya Schoormans, Jan W A Smit, Romana T Netea-Maier, Thera P Links, Winette T A van der Graaf, Olga Husson
BACKGROUND: The purpose of this study was to compare general health-related quality of life (HR-QOL) of thyroid cancer survivors with a normative sample stratified by age at diagnosis (adolescents and young adults 18-35 years; middle-aged adults 36-64 years; elderly 65-84 years), and to compare general HR-QOL and disease-specific symptoms among adolescents and young adults, middle-aged adults, and elderly thyroid cancer survivors in an exploratory population-based cross-sectional study...
May 13, 2018: Head & Neck
https://www.readbyqxmd.com/read/29755330/the-high-costs-of-low-grade-inflammation-persistent-fatigue-as-a-consequence-of-reduced-cellular-energy-availability-and-non-adaptive-energy-expenditure
#13
REVIEW
Tamara E Lacourt, Elisabeth G Vichaya, Gabriel S Chiu, Robert Dantzer, Cobi J Heijnen
Chronic or persistent fatigue is a common, debilitating symptom of several diseases. Persistent fatigue has been associated with low-grade inflammation in several models of fatigue, including cancer-related fatigue and chronic fatigue syndrome. However, it is unclear how low-grade inflammation leads to the experience of fatigue. We here propose a model of an imbalance in energy availability and energy expenditure as a consequence of low-grade inflammation. In this narrative review, we discuss how chronic low-grade inflammation can lead to reduced cellular-energy availability...
2018: Frontiers in Behavioral Neuroscience
https://www.readbyqxmd.com/read/29753161/engagement-with-inspire-an-online-program-for-hematopoietic-cell-transplantation-survivors
#14
Karen L Syrjala, Marie-Laure Crouch, Wendy M Leisenring, Mary E D Flowers, Samantha B Artherholt, Allison Stover Fiscalini, Eleni Romano, Joan M Romano, Paul J Martin, Jean C Yi
PURPOSE: In a secondary analysis of a randomized controlled trial (RCT), we examined engagement with INSPIRE, a personalized online program for hematopoietic cell transplantation (HCT) survivors that focused on cancer-related distress, depression, fatigue, and health care needs. METHODS: We approached all adult, 3-18 year HCT survivors treated for hematologic malignancy, without relapse or second cancer in the previous 2 years, for participation in an RCT with either immediate or delayed access to INSPIRE...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753101/validation-of-the-amharic-version-of-the-brief-fatigue-inventory-bfi-am-for-assessment-of-cancer-related-fatigue-in-ethiopian-cancer-patients
#15
Girma Tekle Gebremariam, Abel Tesfaye Anshabo, Wondemagegnhu Tigeneh, Ephrem Engidawork
BACKGROUND: Even though cancer related fatigue (CRF) is a highly prevalent and distressing symptom associated with cancer and its treatment; it is mostly under-screened, under-assessed and under-treated. The Brief Fatigue Inventory (BFI) is a reliable and valid instrument to assess CRF. OBJECTIVE: To validate the BFI-Am for assessment of CRF in Ethiopian cancer patients. METHODS: The BFI-Am was developed from its original English version through standard forward-backward translation approach...
May 9, 2018: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#16
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29750398/body-composition-fatigue-and-exercise-in-patients-with-prostate-cancer-undergoing-androgen-deprivation-therapy
#17
Robert U Newton, Emily Jeffery, Daniel A Galvão, Carolyn McIntyre, Nigel Spry, David Joseph, Jim Denham, Dennis R Taaffe
OBJECTIVES: To investigate the association between lean mass (LM) and fat mass (FM) with fatigue and vitality before and following exercise in patients with prostate cancer already undergoing androgen deprivation therapy (ADT). SUBJECTS AND METHODS: Cross-sectional associations between lean and fat mass with fatigue and/or vitality measures were examined in 229 patients (43-90 years). Prospective analysis was undertaken in 129 patients who underwent 3-6 months exercise (predominantly resistance + aerobic)...
May 11, 2018: BJU International
https://www.readbyqxmd.com/read/29747931/efficacy-of-different-leuprolide-administration-schedules-in-premenopausal-breast-cancer-a-retrospective-review
#18
Daniel C Kendzierski, Bryan P Schneider, Patrick J Kiel
BACKGROUND: Leuprolide is a safe and effective treatment of estrogen receptor-positive premenopausal breast cancer. Data from the SOFT/TEXT trials solidified leuprolide in combination with an aromatase inhibitor as an effective hormonal treatment for premenopausal breast cancer. However, the efficacy of monthly leuprolide depot compared to leuprolide depot every 3 months in combination with an aromatase inhibitor in this patient population is unclear. PATIENTS AND METHODS: In this single center retrospective study, 201 patients were enrolled between January 1, 2015, and October 1, 2016; 100 were included in the 7...
April 18, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29745932/analysis-of-tolerance-and-security-of-chemo-hyperthermia-with-mitomycin-c-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#19
Juan León-Mata, José Luis Domínguez, Joan Palou Redorta, Daniel Sousa González, María Alvarez Casal, Alejandro Sousa Escandón, Eva Piñeiro Vázquez
OBJECTIVES: The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge. Hyperthermia (HT) combined with intravesical chemotherapy is used to enhance the effects of chemotherapy. METHODS: A review of the publications was carried out to synthesize the adverse effects (AE) reported by the use of chemohyperthermia (QHT) with Mitomycin-C (MMC). The most relevant data are exposed for each of the devices currently used in the QHT. RESULTS: SYNERGO®: The dropout rate varied between 3-40%, and the AE rate is up to 88%...
May 2018: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/29744674/phase-1-study-of-seviteronel-a-selective-cyp17-lyase-and-androgen-receptor-inhibitor-in-women-with-estrogen-receptor-positive-or-triple-negative-breast-cancer
#20
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L Blackwell, Lisa A Carey, Joel R Eisner, Edwina S Baskin-Bey, Tiffany A Traina
PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK), and activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or ER+ breast cancer. METHODS: Seviteronel was administered in de-escalating 750, 600, and 450 mg QD 6-subject cohorts...
May 9, 2018: Breast Cancer Research and Treatment
keyword
keyword
39569
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"